The Association between Fibroblast Growth Factor-23 and Vascular Calcification Is Mitigated by Inflammation Markers
- PMID: 24348506
- PMCID: PMC3843931
- DOI: 10.1159/000356118
The Association between Fibroblast Growth Factor-23 and Vascular Calcification Is Mitigated by Inflammation Markers
Abstract
Background: Fibroblast growth factor-23 (FGF-23) has been linked to vascular calcification, ventricular hypertrophy and mortality in chronic kidney disease (CKD), although these links may not be direct and independent. Similar grave outcomes are associated with inflammation and oxidative stress in CKD. Recently, accumulating evidence has linked components of phosphate homeostasis to inflammation and oxidative stress. The interaction between the triad of inflammation, FGF-23 and cardiovascular outcomes is underinvestigated.
Methods: We studied 65 patients with stage 5 CKD on hemodialysis. Serum levels of FGF-23, high-sensitivity C-reactive protein (hsCRP), endogenous soluble receptor of advanced glycation end products (esRAGE), advanced oxidation protein products (AOPP), parathormone, lipids, calcium and phosphorous were measured. The aortic calcification index (ACI) was determined using non-contrast CT scans of the abdominal aorta.
Results: FGF-23 was elevated (mean: 4,681 pg/ml, SD: 3,906) and correlated with hsCRP, esRAGE, AOPP, dialysis vintage and phosphorus in univariate analysis. In multiple regression analysis, hsCRP, AOPP and phosphorus but not esRAGE were all significantly correlated to FGF-23 (R2 = 0.7, p < 0.001). In univariate analysis, ACI correlated with hsCRP, esRAGE, FGF-23, dialysis vintage, systolic blood pressure (BP) and serum cholesterol. In multiple regression analysis not including inflammation markers, ACI was associated with FGF-23. However, inclusion of inflammation markers in another multiple regression analyses showed that ACI correlated with hsCRP, BP, dialysis vintage and esRAGE but not with FGF-23 (R2 = 0.65, p < 0.001).
Conclusion: FGF-23 is strongly correlated to various markers of inflammation and oxidative stress in hemodialysis patients. The association between FGF-23 and vascular calcification was mitigated when corrected for inflammation markers.
Keywords: Chronic kidney disease; Chronic kidney disease; Fibroblast growth factor-23; Inflammation markers; Uremic toxins; Vascular calcification.
Similar articles
-
Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients.Int Urol Nephrol. 2012 Aug;44(4):1193-9. doi: 10.1007/s11255-011-0007-x. Epub 2011 Jun 4. Int Urol Nephrol. 2012. PMID: 21643645
-
Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients.Nephrol Dial Transplant. 2010 Aug;25(8):2679-85. doi: 10.1093/ndt/gfq089. Epub 2010 Feb 22. Nephrol Dial Transplant. 2010. PMID: 20176609
-
Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis.Int Urol Nephrol. 2008;40(4):1067-74. doi: 10.1007/s11255-008-9462-4. Epub 2008 Sep 13. Int Urol Nephrol. 2008. PMID: 18791804
-
Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.Ther Adv Cardiovasc Dis. 2013 Dec;7(6):322-42. doi: 10.1177/1753944713513061. Ther Adv Cardiovasc Dis. 2013. PMID: 24327730 Free PMC article. Review.
-
Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease.Int Urol Nephrol. 2014 Jan;46(1):9-17. doi: 10.1007/s11255-012-0370-2. Epub 2013 Jan 8. Int Urol Nephrol. 2014. PMID: 23296792 Review.
Cited by
-
FGF-23 levels in patients with critical carotid artery stenosis.Intern Emerg Med. 2015 Jun;10(4):437-44. doi: 10.1007/s11739-014-1183-3. Epub 2015 Jan 9. Intern Emerg Med. 2015. PMID: 25573621
-
Fibroblast growth factor-23 correlates with advanced disease conditions and predicts high risk of major adverse cardiac and cerebral events in end-stage renal disease patients undergoing continuous ambulatory peritoneal dialysis.J Nephrol. 2019 Apr;32(2):307-314. doi: 10.1007/s40620-018-0557-4. Epub 2018 Nov 21. J Nephrol. 2019. PMID: 30465136
-
Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility.Am J Physiol Endocrinol Metab. 2018 Oct 1;315(4):E594-E604. doi: 10.1152/ajpendo.00343.2017. Epub 2018 Mar 20. Am J Physiol Endocrinol Metab. 2018. PMID: 29558205 Free PMC article.
-
Extrarenal effects of FGF23.Pediatr Nephrol. 2017 May;32(5):753-765. doi: 10.1007/s00467-016-3505-3. Epub 2016 Oct 4. Pediatr Nephrol. 2017. PMID: 27704252 Review.
-
Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review.J Adv Res. 2017 May;8(3):271-278. doi: 10.1016/j.jare.2017.02.003. Epub 2017 Feb 27. J Adv Res. 2017. PMID: 28337344 Free PMC article. Review.
References
-
- Donate-Correa J, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF. FGF23/Klotho axis: phosphorus, mineral metabolism and beyond. Cytokine Growth Factor Rev. 2012;23:37–46. - PubMed
-
- Gonzalez-Parra E, Tuñón J, Egido J, Ortiz A. Phosphate: a stealthier killer than previously thought? Cardiovasc Pathol. 2012;21:372–381. - PubMed
-
- Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010;21:1427–1435. - PubMed
-
- Ketteler M, Biggar PH, Liangos O. FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease. Nephrol Dial Transplant. 2013;28:821–825. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials